On August 29, 2022, MIT Science Policy Review featured insights from AFAR Scientific Director Nir Barzilai, MD, and AFAR grantee Matt Kaeberlein, PhD, discussing the biology of aging, therapeutic interventions, and the upcoming AFAR-managed TAME Trial.
In addition to serving as AFAR’s Scientific Director, Dr. Barzilai is a 1994 Glenn Foundation for Medical Research and AFAR Grants for Junior Faculty recipient, a 1997 Paul B. Beeson Emerging Leaders Career Development Award in Aging scholar, a 2010 Irving S. Wright Award of Distinction recipient, and the Director at the Institute for Aging Research and distinguished Professor at the Albert Einstein College of Medicine.
Dr. Kaeberlein is a 2006 Glenn Foundation for Medical Research and AFAR Grants for Junior Faculty recipient, and a 2007 Glenn Foundation for Medical Research Breakthroughs in Gerontology (BIG) Award recipient. He is also the Co-Director at the University of Washington Nathan Shock Center of Excellence in the Basic Biology of Aging, the Director of the Healthy Aging and Longevity Research Institute, the President of the American Aging Association, the Co-Director of the Dog Aging Project, and a Professor at the University of Washington.
Read the article, “The Future of Treating Aging,” here.
Learn more about the TAME Trial here.
